Regulatory Doctor
Regulatory Doctor is a consulting firm specializing in FDA regulatory compliance, offering tailored solutions for pharmaceutical, biotechnology, and medical device sectors. They focus on navigating FDA pathways, securing approvals, and ensuring market entry in global markets. Their approach is client-centered, emphasizing collaboration, transparency, and customized strategies to achieve regulatory success. They also provide training, mock audits, and inspection preparation to facilitate compliance and market access. Recently, they have expanded their expertise to include support for rare disease treatments, such as Crenessity for CAH, and are integrating AI-driven solutions to enhance medical and regulatory writing, data analysis, and strategic planning.
Industries
Nr. of Employees
small (1-50)
Regulatory Doctor
Products
Regulatory Compliance Consulting Services
Consulting services focused on helping companies in the biotech, pharma, and medical device sectors achieve FDA regulatory compliance.
Regulatory Compliance Consulting Services
Consulting services focused on helping companies in the biotech, pharma, and medical device sectors achieve FDA regulatory compliance.
Business Strategy Consulting
Consulting services aimed at helping small businesses develop growth strategies by identifying strengths, weaknesses, opportunities, and threats.
Business Strategy Consulting
Consulting services aimed at helping small businesses develop growth strategies by identifying strengths, weaknesses, opportunities, and threats.
Marketing Consulting
Services designed to assist small businesses in creating marketing plans to drive growth and increase revenue.
Marketing Consulting
Services designed to assist small businesses in creating marketing plans to drive growth and increase revenue.
Regulatory Compliance Consulting Services
Consulting services focused on helping companies in the biotech, pharma, and medical device sectors achieve FDA regulatory compliance.
Regulatory Compliance Consulting Services
Consulting services focused on helping companies in the biotech, pharma, and medical device sectors achieve FDA regulatory compliance.
Business Strategy Consulting
Consulting services aimed at helping small businesses develop growth strategies by identifying strengths, weaknesses, opportunities, and threats.
Business Strategy Consulting
Consulting services aimed at helping small businesses develop growth strategies by identifying strengths, weaknesses, opportunities, and threats.
Marketing Consulting
Services designed to assist small businesses in creating marketing plans to drive growth and increase revenue.
Marketing Consulting
Services designed to assist small businesses in creating marketing plans to drive growth and increase revenue.
Services
End‑to‑end regulatory planning covering pathway selection, gap analysis, designation support, and submission roadmaps for drugs, biologics, and devices.
Drafting and management of regulatory filings (510(k), PMA, IDE, NDA, BLA, IND, ANDA, supplements) including interactive review support and coordinated CMC/clinical inputs.
Preparation of meeting packages and briefing documents, and tactical advice for Pre‑Submissions and formal meetings with regulators.
Compliance assessments, protocol development, facility audits, process validation, QMS implementation, training, and inspection preparation across GLP, GMP, and GCP.
Protocol design, endpoint selection, and data strategy alignment for INDs and pivotal submissions, including monitoring and oversight planning.
Conduct mock regulatory inspections, prepare inspection responses, and implement corrective and preventive actions to remediate audit findings.
End‑to‑end regulatory planning covering pathway selection, gap analysis, designation support, and submission roadmaps for drugs, biologics, and devices.
Drafting and management of regulatory filings (510(k), PMA, IDE, NDA, BLA, IND, ANDA, supplements) including interactive review support and coordinated CMC/clinical inputs.
Preparation of meeting packages and briefing documents, and tactical advice for Pre‑Submissions and formal meetings with regulators.
Compliance assessments, protocol development, facility audits, process validation, QMS implementation, training, and inspection preparation across GLP, GMP, and GCP.
Protocol design, endpoint selection, and data strategy alignment for INDs and pivotal submissions, including monitoring and oversight planning.
Conduct mock regulatory inspections, prepare inspection responses, and implement corrective and preventive actions to remediate audit findings.
Expertise Areas
- Regulatory strategy and pathway planning (US and international)
- Regulatory submissions and dossier development (drugs, biologics, devices)
- Clinical trial design and GCP compliance
- GMP and manufacturing quality systems
Key Technologies
- Gene therapy (viral vector delivery)
- Monoclonal antibody therapeutics
- Liposomal drug delivery formulations
- Hot melt extrusion for modified‑release formulations
News & Updates
FDA's Rule on Hard-to-Compound Drugs: A Regulatory Milestone
The FDA proposes a rule establishing criteria for identifying drugs difficult to compound, focusing on formulation, bioavailability, sterility, safety, and analytical challenges. The rule aims to enhance patient safety and regulate compounded drugs, with timelines for public comment, finalization, and implementation.
FDA Approves Crenessity for CAH: A Breakthrough for Patients
The FDA has approved Crenessity (crinecerfont), a novel therapy for classic congenital adrenal hyperplasia (CAH), marking a significant advance in treatment options. Regulatory Doctor supported the development and approval process, leveraging expertise in rare disease drug development, expedited pathways like Orphan Drug, Fast Track, and Breakthrough Therapy Designation, and post-approval compliance strategies.
FDA's Rule on Hard-to-Compound Drugs: A Regulatory Milestone
The FDA proposes a rule establishing criteria for identifying drugs difficult to compound, focusing on formulation, bioavailability, sterility, safety, and analytical challenges. The rule aims to enhance patient safety and regulate compounded drugs, with timelines for public comment, finalization, and implementation.
FDA Approves Crenessity for CAH: A Breakthrough for Patients
The FDA has approved Crenessity (crinecerfont), a novel therapy for classic congenital adrenal hyperplasia (CAH), marking a significant advance in treatment options. Regulatory Doctor supported the development and approval process, leveraging expertise in rare disease drug development, expedited pathways like Orphan Drug, Fast Track, and Breakthrough Therapy Designation, and post-approval compliance strategies.